More Than 2 Decades of Treating Atypical Fibroxanthoma at Mayo Clinic: What Have We Learned From 91 Patients?

Mayo CLinic Rochester, Minnesota 55905, USA.
Dermatologic Surgery (Impact Factor: 2.11). 04/2009; 35(5):765-72. DOI: 10.1111/j.1524-4725.2009.01126.x
Source: PubMed


Atypical fibroxanthoma (AFX) typically occurs on the head and neck of elderly white men. Usually considered a malignancy, it is treated with wide local excision (WLE) or total margin control using Mohs micrographic surgery (MMS).
To determine the most appropriate treatment for this tumor based on a review of cases treated at Mayo Clinic.
We reviewed the medical records of patients with AFX treated at Mayo Clinic from 1980 to 2004.
We identified 91 patients with 93 tumors. Treatment information was available for 88 tumors (59 treated with MMS, 23 with WLE, and 6 by other means). There were no recurrences in the patients treated with MMS, with a median follow-up of 4.5 years (range 1.0-16.1 years). Two patients treated with WLE had single recurrences, with a median follow-up of 8.7 years (range 1.5-26.3 years).
Total microscopic margin control using MMS was the most effective means of treating AFX.

22 Reads
  • [Show abstract] [Hide abstract]
    ABSTRACT: Soft tissue sarcomas are uncommon tumors. Accurate pretreatment evaluation plays an important role in treating Soft tissue sarcomas. The growth rate and relative recurrence rate of soft tissue sarcomas varies with the aggressiveness of the tumor. A 67-year-old man was diagnosed with atypical fibroxanthoma in the right lower leg, which subsequently recurred, after resection, as a myxofibrosarcoma and metastatic lymph nodes in the right lower pelvis and right groin. Close follow-up with appropriate functional imaging (such as thallium-201 scintigraphy and FDG PET) may aid in the early detection of malignant transformation and metastatic disease.
    No preview · Article · Dec 2009 · Clinical nuclear medicine
  • [Show abstract] [Hide abstract]
    ABSTRACT: Atypical fibroxanthoma is a rare mesenchymal tumour of skin that develops on skin of elderly patients. We analysed our patients with atypical fibroxanthoma over the last 8 years. We analysed the pathology files of our hospital for the period 2001-2009. In all cases, histology and immunohistology were performed. Data on co-morbidities, treatment and outcome were obtained. We identified 25 patients (except two female patients, the rest were men) aged 52-95 years (mean: 79.5 years; standard deviation +/- 9.06 years). All tumours were localized in the head and neck region, except a single tumour on the shoulder. Fourteen patients had a cancer history, six had actinic keratoses or Bowen's disease (n = 1). Five patients had cardiac surgery or pacemaker, one each had a renal transplant, systemic sarcoidosis or non-Hodgkin's lymphoma. Medical history was positive for radiotherapy or chemotherapy in four patients. Histology showed a spindle-shaped dermal and subcutaneous tumour growth intermingled with multinucleated giant cells. The phenotype of tumour cells was vimentin-positive, but S100- and keratin-negative. Some tumours showed a focal expression of CD68. Complete microhistographic controlled surgery ('Mohs like') was possible in all cases followed by mesh-graft transplantation in three patients. Eighteen patients showed a complete remission. Four patients had a relapse within 2 years of follow-up treated by surgery. One patient is still under radiotherapy. All patients with a safety margin of 2 cm had no recurrence or relapse during follow-up. Micrographic controlled surgery with wide 2 cm safety margins is the treatment of choice. A regular follow-up for the next 5 years is recommended.
    No preview · Article · Feb 2010 · Journal of the European Academy of Dermatology and Venereology
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The clinical and histological features of 171 atypical fibroxanthomas (AFX) from a single institution in Western Australia are outlined. This area experiences high levels of solar radiation, and all assessable biopsies showed solar elastosis. Patients were aged between 41 and 97 years (median age 74), with 76% of tumors occurring in men (male to female ratio approximately 3 to 1). Most tumors were small, with a median diameter of 10 mm and a range of 4-35 mm. Only 5% exceeded 20 mm in diameter. Most AFX were well-circumscribed dermal lesions, with limited invasion of subcutis in a minority. Histological variants identified included keloidal (n = 8), clear cell (n = 3), and granular cell (n = 3), plaque like (n = 4), and myxoid (n = 1). Bland cytological appearances (spindle cell nonpleomorphic AFX) were noted in 5 tumors, with osteoclast-like giant cells in 2. Features suggesting regression were present in 22 cases. Two cases recurred locally, none metastasized. No tumors expressed melanocytic or epithelial markers. Seventy-four percent of cases expressed smooth muscle actin, typically strongly and diffusely. No AFX stained with desmin. Only 1 of 50 cases was CD117 positive. In conclusion, AFX may show a wide range of histological appearances, and a panel of immunohistochemical markers is essential to make the correct diagnosis. Histological mimics, such as poorly differentiated squamous cell carcinoma, must be carefully excluded. Specific diagnosis is important because there seems to be a very low risk of recurrence or metastasis despite the frequently alarming histology.
    Full-text · Article · Aug 2010 · The American Journal of dermatopathology
Show more